FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sandra Dunn

Research Profile

Chemicals & Drugs

Disorders

Breast Neoplasms

Anatomy

Physiology

Co-author Network

Publications

TOP 3
Kristen M Reipas; Amarpal S Cheema; Artem Cherkasov; Nicole Couto; John A Hassell; Sumaiya Islam; Steven J M Jones; Karen Jung; Jennifer H Law; Huifang Li; Yvonne Li; Sandra E Dunn
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Pooja Mohan; Oksana Nemirovsky; Miguel Angel Pujana; Melanie Spyra; Alberto Villanueva; Kristi Allen; Joan Castellsague; Helen Chen; Sandra E Dunn; Kaiji Hu; Jihong Jiang; Jonathan J Keats; Lan Kluwe; Conxi Lazaro; Victor F Mautner; Christopher A Maxwell
Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
Annette Lasham; Cristin G Print; Adele G Woolley; Sandra E Dunn; Antony W Braithwaite
YB-1: oncoprotein, prognostic marker and therapeutic target?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sandra Dunn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kristen M Reipas; Amarpal S Cheema; Artem Cherkasov; Nicole Couto; John A Hassell; Sumaiya Islam; Steven J M Jones; Karen Jung; Jennifer H Law; Huifang Li; Yvonne Li; Sandra E Dunn
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Oncotarget 2013;4(2):329-45.
2013: Pooja Mohan; Oksana Nemirovsky; Miguel Angel Pujana; Melanie Spyra; Alberto Villanueva; Kristi Allen; Joan Castellsague; Helen Chen; Sandra E Dunn; Kaiji Hu; Jihong Jiang; Jonathan J Keats; Lan Kluwe; Conxi Lazaro; Victor F Mautner; Christopher A Maxwell
Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
Oncotarget 2013;4(1):80-93.
2013: Annette Lasham; Cristin G Print; Adele G Woolley; Sandra E Dunn; Antony W Braithwaite
YB-1: oncoprotein, prognostic marker and therapeutic target?
The Biochemical journal 2013;449(1):11-23.
2012: A Astanehe; I M Berquin; J Dhillon; M R Finkbeiner; Abbas Fotovati; M Krzywinski; M A Marra; G B Mills; Sandra E Dunn
MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Oncogene 2012;31(41):4434-46.
2012: Joanna Triscott; Stephen Yip; Rachel Berns; Abbas Fotovati; Kaiji Hu; Richard E Kast; Esther Kong; Cathy Lee; Margaret Luk; Mary Pambid; Brian Toyota; Eric Toyota; Sandra E Dunn
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Oncotarget 2012;3(10):1112-23.
2012: Anna L Stratford; Mandeep Takhar; Peter Watson; Alan Ashworth; Rachel Brough; Abbas Fotovati; Jessica Frankum; Kaiji Hu; Annette Lasham; Christopher J Lord; Cristin G Print; Kristen Reipas; Sandra E Dunn
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stem cells (Dayton, Ohio) 2012;30(7):1338-48.
2012: Cathy Lee; Aru Narendran; Sheila K Singh; Ash Singhal; Joanna Triscott; Chitra Venugopal; Maite Verreault; Hiroaki Wakimoto; Stephen Yip; Abbas Fotovati; Aarthi Jayanthan; Chris Jones; John M Kerr; James Chen; Christopher Dunham; Sandra E Dunn
Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Stem cells (Dayton, Ohio) 2012;30(6):1064-75.
2012: Cathy Lee; Sandra E Dunn; Stephen Yip
Stem cells in brain tumour development and therapy- two-sides of the same coin.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2012;39(2):145-56.
2012: Kaiji Hu; Jennifer H Law; Abbas Fotovati; Sandra E Dunn
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Breast cancer research : BCR 2012;14(1):R22.
2011: A H Davies; I Barrett; I M Berquin; Spencer Alexander Freeman; P Hieter; K Hu; C Maxwell; M R Pambid; S Pelech; A L Stratford; Sandra E Dunn
YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification.
Oncogene 2011;30(34):3649-60.
2011: Abbas Fotovati; Sonia Franciosi; Chris Jones; Alexa Jury; Michihiko Kuwano; Blair R Leavitt; Cathy Lee; Yasuhiro Nakamura; Catherine J Pallen; Brent A Reynolds; Sheila K Singh; Yasuo Sugita; Joanna Triscott; Takeshi Uchiumi; Hiroaki Wakimoto; Pei-Shan Wang; Samah Abu-Ali; James Y Chen; Loic P Deleyrolle; Sandra E Dunn
YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth.
Cancer research 2011;71(16):5569-78.
2011: Alastair H Davies; Sandra E Dunn
YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention.
Oncotarget 2011;2(5):401-6.
2011: Anna L Stratford; Sandra E Dunn
The promise and challenges of targeting RSK for the treatment of cancer.
Expert opinion on therapeutic targets 2011;15(1):1-4.
2010: J Kalra; B W Sutherland; A L Stratford; Wieslawa H Dragowska; Karen Gelmon; Shoukat Dedhar; Sandra E Dunn; Marcel B Bally
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.
Oncogene 2010;29(48):6343-56.
2010: J Dhillon; A Astanehe; Cathy Lee; Abbas Fotovati; K Hu; Sandra E Dunn
The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Oncogene 2010;29(47):6294-300.
2010: Karen To; Abbas Fotovati; Kristen M Reipas; Jennifer H Law; Kaiji Hu; Jing Wang; Arezoo Astanehe; Alastair H Davies; Lawrence Lee; Anna L Stratford; Afshin Raouf; Pauline Johnson; Isabelle M Berquin; Hans-Dieter Royer; Connie J Eaves; Sandra E Dunn
Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.
Cancer research 2010;70(7):2840-51.
2010: Jennifer H Law; Yvonne Li; Karen To; Michelle Wang; Arezoo Astanehe; K Lambie; Jaspreet Dhillon; Steven J M Jones; Martin E Gleave; Connie J Eaves; Sandra E Dunn
Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
PloS one 2010;5(9):.
2010: Anna L Stratford; Kristen Reipas; Christopher Maxwell; Sandra E Dunn
Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.
Expert reviews in molecular medicine 2010;12():e22.
2009: Yuanyuan Gao; Abbas Fotovati; Cathy Lee; Michelle Wang; Gilbert Cote; Emma S Guns; Brian Toyota; Damien Faury; Nada Jabado; Sandra E Dunn
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Molecular cancer therapeutics 2009;8(12):3276-84.
2009: Kaiji Hu; Cathy Lee; Dexin Qiu; Abbas Fotovati; Alastair Davies; Samah Abu-Ali; Daniel Wai; Elizabeth Lawlor; Timothy Triche; Catherine J Pallen; Sandra E Dunn
Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
Molecular cancer therapeutics 2009;8(11):3024-35.
2009: A Astanehe; M R Finkbeiner; P Hojabrpour; K To; A Fotovati; Ashleen Shadeo; A L Stratford; Wan L Lam; I M Berquin; V Duronio; Sandra E Dunn
The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
Oncogene 2009;28(25):2406-18.
2009: M R Finkbeiner; A Astanehe; K To; A Fotovati; A H Davies; Y Zhao; H Jiang; A L Stratford; Ashleen Shadeo; C Boccaccio; P Comoglio; P R Mertens; Peter Eirew; A Raouf; Connie J Eaves; Sandra E Dunn
Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
Oncogene 2009;28(11):1421-31.
2008: Cathy Lee; Jaspreet Dhillon; Michelle Y C Wang; Yuanyuan Gao; Kaiji Hu; Eugene Park; Arezoo Astanehe; Mien-Chie Hung; Peter Eirew; Connie J Eaves; Sandra E Dunn
Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
Cancer research 2008;68(21):8661-6.
2008: Anna L Stratford; Christopher J Fry; Curtis Desilets; Alastair H Davies; Yong Y Cho; Yvonne Li; Zigang Dong; Isabelle M Berquin; Philippe Roux; Sandra E Dunn
Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Breast cancer research : BCR 2008;10(6):R99.
2008: Golareh Habibi; Samuel Leung; Jennifer H Law; Karen Gelmon; Hamid Masoudi; Dmitry Turbin; Michael Pollak; Torsten O Nielsen; David Huntsman; Sandra E Dunn
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Breast cancer research : BCR 2008;10(5):R86.
2007: K To; Y Zhao; H Jiang; K Hu; M Wang; Joyce Wu; Cathy Lee; Daniel Yokom; A L Stratford; U Klinge; P R Mertens; Ching-Shih Chen; Marcel B Bally; D Yapp; Sandra E Dunn
The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
Molecular pharmacology 2007;72(3):641-52.
2007: Nancy Dos Santos; Timothy Triche; Michelle Wang; Daniel Wei; Heather N Andrews; Shoukat Dedhar; Golareh Habibi; Jennifer H Law; Sandra E Dunn
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK).
Translational oncogenomics 2007;2():85-97.
2007: Joyce Wu; Anna L Stratford; Arezoo Astanehe; Sandra E Dunn
YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression.
Translational oncogenomics 2007;2():49-65.
2007: Anna L Stratford; Golareh Habibi; Arezoo Astanehe; Helen Jiang; Kaiji Hu; Eugene Park; Ashleen Shadeo; Timon P H Buys; Wan Lam; Trevor Pugh; Marco Marra; Torsten O Nielsen; Uwe Klinge; Peter R Mertens; Samuel Aparicio; Sandra E Dunn
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
Breast cancer research : BCR 2007;9(5):R61.
2006: Joyce Wu; Cathy Lee; Daniel Yokom; Helen Jiang; Mary Cheang; Erika Yorida; Dmitry Turbin; Isabelle M Berquin; Peter R Mertens; Thomas Iftner; C Blake Gilks; Sandra E Dunn
Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
Cancer research 2006;66(9):4872-9.
2006: Armelle A Troussard; Paul C McDonald; Elizabeth D Wederell; Nasrin M Mawji; Nolan R Filipenko; Karen Gelmon; Jill E Kucab; Sandra E Dunn; Joanne T Emerman; Marcel B Bally; Shoukat Dedhar
Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
Cancer research 2006;66(1):393-403.
2005: Heather N Andrews; Golerah Habibi; Jill E Kucab; Sandra E Dunn
Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
Breast cancer research and treatment 2005;94(1):47-52.
2005: Brent W Sutherland; Jill Kucab; Joyce Wu; Cathy Lee; Mary Cheang; Erika Yorida; Dmitry Turbin; Shoukat Dedhar; Colleen Nelson; Michael Pollak; H Leighton Grimes; Kathy D Miller; Sunil Badve; David Huntsman; C Blake-Gilks; Min Chen; Catherine J Pallen; Sandra E Dunn
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.
Oncogene 2005;24(26):4281-92.
2005: Jill E Kucab; Cathy Lee; Ching-Shih Chen; Jiuxiang Zhu; C Blake Gilks; Mary Cheang; David Huntsman; Erika Yorida; Joanne T Emerman; Michael Pollak; Sandra E Dunn
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.
Breast cancer research : BCR 2005;7(5):R796-807.
2004: Nikita Makretsov; David Huntsman; Torsten O Nielsen; Erika Yorida; Michael Peacock; Mary Cheang; Sandra E Dunn; Malcolm Hayes; Matt van de Rijn; Chris D Bajdik; C Blake Gilks
Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6143-51.
2004: Torsten O Nielsen; Heather N Andrews; Mary Cheang; Jill E Kucab; Forrest D Hsu; Joseph Ragaz; C Blake Gilks; Nikita Makretsov; Chris D Bajdik; Christy Brookes; Leonard M Neckers; Valentina Evdokimova; David Huntsman; Sandra E Dunn
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
Cancer research 2004;64(1):286-91.
2003: Jill E Kucab; Sandra E Dunn
Role of IGF-1R in mediating breast cancer invasion and metastasis.
Breast disease 2003;17():41-7.
2002: J S Oh; Jill E Kucab; Pierre R Bushel; K Martin; Lee Bennett; J Collins; Richard P DiAugustine; J Carl Barrett; Cynthia A Afshari; Sandra E Dunn
Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells.
Neoplasia (New York, N.Y.) 2002;4(3):204-17.
2001: Sandra E Dunn; J V Torres; J S Oh; D M Cykert; J Carl Barrett
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
Cancer research 2001;61(4):1367-74.
2000: Sandra E Dunn
Insulin-like growth factor I stimulates angiogenesis and the production of vascular endothelial growth factor.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2000;10 Suppl A():S41-2.
2000: Sandra E Dunn; J V Torres; N Nihei; J Carl Barrett
The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy.
Molecular carcinogenesis 2000;27(1):10-7.
1999: Frank W Kari; Sandra E Dunn; John E French; J Carl Barrett
Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction.
The journal of nutrition, health & aging 1999;3(2):92-101.
1998: Sandra E Dunn; M Ehrlich; N J Sharp; K Reiss; Greg Solomon; R Hawkins; R Baserga; J Carl Barrett
A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.
Cancer research 1998;58(15):3353-61.
1998: Samantha Steingold; Nicholas J H Sharp; M Christine McGahan; CS Hughes; Sandra E Dunn; Rodney L Page
Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo.
Anticancer research 1998;18(1A):393-400.
1997: Sandra E Dunn; Frank W Kari; J French; J Leininger; Gregory S Travlos; R Wilson; J Carl Barrett
Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice.
Cancer research 1997;57(21):4667-72.
1997: John M Cullen; S L Smith; M G Davis; Sandra E Dunn; C Botteron; A Cecchi; D Linsey; D Linzey; Lloyd Frick; M T Paff; A Goulding; Karen K Biron
In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.
Antimicrobial agents and chemotherapy 1997;41(10):2076-82.
1997: Sandra E Dunn; R A Hardman; Frank W Kari; J Carl Barrett
Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.
Cancer research 1997;57(13):2687-93.
1996: Sandra E Dunn; J M Cullen
Woodchuck p-glycoprotein found in virus-induced hepatocellular carcinomas binds anticancer drugs.
Cancer letters 1996;110(1-2):177-80.
1996: Sandra E Dunn; C S Hughes; Gerald A LeBlanc; J M Cullen
Overexpression of a p-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Marmota monax).
Hepatology (Baltimore, Md.) 1996;23(4):662-8.
1994: Gerald A LeBlanc; J D Stuart; Sandra E Dunn; William S Baldwin
Effect of the plant compound indole-3-carbinol on hepatic cholesterol homoeostasis.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 1994;32(7):633-9.
1994: Sandra E Dunn; Gerald A LeBlanc
Hypocholesterolemic properties of plant indoles. Inhibition of acyl-CoA:cholesterol acyltransferase activity and reduction of serum LDL/VLDL cholesterol levels by glucobrassicin derivatives.
Biochemical pharmacology 1994;47(2):359-64.